Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05291091 |
|
Recruitment Status :
Recruiting
First Posted : March 22, 2022
Last Update Posted : March 27, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
A study of EDG-5506 in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EDG-5506 in adults with Becker.
CANYON is fully enrolled; GRAND CANYON is currently enrolling.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Becker Muscular Dystrophy | Drug: EDG-5506 10 mg Drug: EDG-5506 5 mg Drug: EDG-5506 12.5 mg Drug: Placebo | Phase 2 |
The EDG-5506-201 protocol was amended to include an additional cohort thus consists of two parts.
Part 1: CANYON is a double-blind, randomized, placebo-controlled design to investigate the effect of EDG-5506 on the safety, pharmacokinetics, biomarkers, and functional measures. Approximately 32 adults and 18 adolescents with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, a 12-month Treatment period, followed by a 4-week follow-up period.
Approximately 32 adult participants will randomize to Cohort 1 or Cohort 2 in a 1:1 ratio then each cohort will further randomize to EDG-5506 or placebo in a 3:1 ratio.
Approximately 9 adolescent participants will enroll in Cohort 4 and randomize in a 2:1 ratio to EDG-5506 or placebo. Cohort 5 will randomize an additional 9 participants in a 2:1 ratio to either EDG-5506 or placebo after Cohort 4.
CANYON is now fully enrolled.
Part 2: GRAND CANYON or Cohort 6 is a double-blind, randomized, placebo-controlled design to investigate the safety and efficacy of EDG-5506 in adults with Becker muscular dystrophy after 18 months of treatment. Approximately 120 adults with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, an 18-month Treatment period, followed by a 4-week follow-up period.
Approximately 120 adult participants will be randomized in Cohort 6 in a 2:1 ratio either to EDG-5506 or placebo.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 170 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy |
| Actual Study Start Date : | July 6, 2022 |
| Estimated Primary Completion Date : | June 2026 |
| Estimated Study Completion Date : | June 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Adult Cohort 1
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 10 mg
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
|
Experimental: Adult Cohort 2
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 10 mg
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
|
Experimental: Adult Cohort 6
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 10 mg
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
|
Experimental: Adolescent Cohort 4
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 5 mg
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
|
Experimental: Adolescent Cohort 5
Drug: EDG-5506 Drug: Placebo
|
Drug: EDG-5506 12.5 mg
EDG-5506 is administered orally once per day Drug: Placebo Placebo is administered orally once per day |
- Number of adverse events in those treated with EDG-5506 or placebo [ Time Frame: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6) ]All participants
- Severity of adverse events in those treated with EDG-5506 or placebo [ Time Frame: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6) ]All participants
- Change from Baseline in serum Creatine Kinase [ Time Frame: 12 Months (CANYON Cohorts 1, 2) ]Adult participants
- Change from Baseline in the North Star Ambulatory Assessment scale [ Time Frame: 18 months (GRAND CANYON Cohort 6) ]Adult participants
- Change from Baseline in the protein fast skeletal muscle Troponin I [ Time Frame: 12 months (CANYON Cohorts 1, 2), 18 months (GRAND CANYON Cohort 6) ]Adult participants
- Change from Baseline in the North Star Ambulatory Assessment scale [ Time Frame: 12 Months (CANYON Cohorts 1, 2) ]Adult participants
- Change from Baseline in the North Star Assessment for Limb-Girdle Type Muscular Dystrophies scale [ Time Frame: 12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6) ]Adult participants
- Change from Baseline in the 10-meter walk/run test [ Time Frame: 12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6) ]Adult participants
- Change from Baseline in 100-meter timed test [ Time Frame: 12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6) ]Adult participants
- Change from Baseline in stride velocity (95th percentile) [ Time Frame: 18 Months (GRAND CANYON Cohort 6) ]Adult participants
- Pharmacokinetics as measured by steady state plasma concentration [ Time Frame: 12 Months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6) ]All participants
- Change from Baseline in growth as assessed by height centile on World Health Organization growth charts [ Time Frame: 12 months (CANYON Cohorts 4, 5) ]Adolescent participants
- Month 18 change from Baseline in fat fraction of upper leg muscles as assessed by Magnetic Resonance Imaging [ Time Frame: 18 months (GRAND CANYON Cohort 6) ]Adult participants
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years to 50 Years (Child, Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
The CANYON Study including the adolescent cohorts are fully enrolled.
GRAND CANYON eligibility is listed below.
Key Inclusion Criteria:
- Adults (aged 18 to 50 years, inclusive) with a documented dystrophin mutation and phenotype consistent with Becker muscular dystrophy, and history of being ambulatory beyond 16 years of age without steroids; history of being ambulatory beyond 18 years of age with steroids.
- Able to complete the 100-meter timed test in < 200 seconds with or without use of mobility aid devices.
- Able to perform the North Star Ambulatory Assessment scale and achieve a score of 5 to 32, inclusive.
Key Exclusion Criteria:
- Medical history or clinically significant physical examination/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes contraindications to magnetic resonance imaging such as non-compatible implanted medical devices or severe claustrophobia.
- Cardiac echocardiogram ejection fraction < 40%
- Forced vital capacity predicted <60% or using daytime ventilatory support
- Receipt of oral corticosteroids for the treatment of BMD in the previous 6 months.
- Receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit in the present study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05291091
| Contact: Edgewise Therapeutics | 720-262-7002 | studies@edgewisetx.com |
Show 19 study locations
| Study Chair: | Joanne Donovan, MD, PhD | Edgewise Therapeutics, Inc. |
| Responsible Party: | Edgewise Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT05291091 |
| Other Study ID Numbers: |
EDG-5506-201 |
| First Posted: | March 22, 2022 Key Record Dates |
| Last Update Posted: | March 27, 2024 |
| Last Verified: | March 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Becker Muscular Dystrophy |
|
Muscular Dystrophies Muscular Dystrophy, Duchenne Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases |
Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn Genetic Diseases, X-Linked |